Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry D Anderson

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Leukemia Research|December 7, 2020
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvementColin P Bergstrom, Saurabh Dahiya, Weina Chen, et al.
Hemasphere|July 3, 2026
Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myelomaBruno Paiva, Irene Manrique, Ethan Thompson, et al.
Leukemia Research|December 25, 2022
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohortNaveen Premnath, Stephen S Chung, Olga K Weinberg, et al.
Contemporary Clinical Trials Communications|April 16, 2024
Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel programChika Nwachukwu, Sukh Makhnoon, Marieshia Person, et al.
Hematological Oncology|February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myelomaAjai Chari, Robert F Cornell, Cristina Gasparetto, et al.
Blood Cancer Discovery|July 24, 2023
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene VicleucelBruno Paiva, Irene Manrique, Julie Rytlewski, et al.
Blood Cancer Journal|June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaSundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Hemasphere|August 21, 2025
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplantBenjamin A Derman, Jennifer Cooperrider, Anna Pula, et al.
Transplantation and Cellular Therapy|December 27, 2023
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World ExperienceDanai Dima, James A Davis, Nausheen Ahmed, et al.
Advances in Therapy|March 24, 2026
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USASikander Ailawadhi, Doris K Hansen, Binod Dhakal, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Leukemia Research|December 7, 2020
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvementColin P Bergstrom, Saurabh Dahiya, Weina Chen, et al.
Hemasphere|July 3, 2026
Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myelomaBruno Paiva, Irene Manrique, Ethan Thompson, et al.
Leukemia Research|December 25, 2022
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohortNaveen Premnath, Stephen S Chung, Olga K Weinberg, et al.
Contemporary Clinical Trials Communications|April 16, 2024
Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel programChika Nwachukwu, Sukh Makhnoon, Marieshia Person, et al.
Hematological Oncology|February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myelomaAjai Chari, Robert F Cornell, Cristina Gasparetto, et al.
Blood Cancer Discovery|July 24, 2023
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene VicleucelBruno Paiva, Irene Manrique, Julie Rytlewski, et al.
Blood Cancer Journal|June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaSundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Hemasphere|August 21, 2025
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplantBenjamin A Derman, Jennifer Cooperrider, Anna Pula, et al.
Transplantation and Cellular Therapy|December 27, 2023
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World ExperienceDanai Dima, James A Davis, Nausheen Ahmed, et al.
Advances in Therapy|March 24, 2026
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USASikander Ailawadhi, Doris K Hansen, Binod Dhakal, et al.
Pageof 12